News

Articles

Through the acquisition, Merck will have access to Pandion’s pipeline of precision immune modulators targeting critical immune control nodes, including its lead candidate, PT101.

Merck to Acquire Pandion Therapeutics for $1.85 Billion

Distribution of the first one-dose vaccine for COVID-19 to start in early March.

J&J Vaccine Approved for Emergency Use

The companies will co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications.

Eli Lilly to Collaborate with Rigel Pharmaceuticals for $960 Million 

The acquisition will allow Charles River to expand its cell and gene therapy development, testing, and manufacturing capabilities, while adding to its existing portfolio of non-clinical capabilities.

Charles River to Acquire Cognate BioServices for $875 Million

The company has pleaded guilty to violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to FDA investigators and will pay a criminal fine of $30 million, and forfeit an additional $20 million.

Fresenius Kabi Oncology Pleads Guilty to Concealing and Destroying Records Prior to FDA Inspection

MTEM will handle research activities for the discovery of the next generation of engineered toxin bodies using its ETB platform, while Bristol Myers Squibb will obtain a license to develop and commercialize the ETBs.

Bristol Myers Squibb and Molecular Templates Form $1.37-Billion R&D Collaboration

The US government will pay $1.95 billion for the additional 100 million doses, bringing the total number of doses supplied by the companies up to 300 million.

Pfizer and BioNTech to Supply 100 Million Additional Doses of COVID-19 Vaccine to United States

The company has divested its specialty ingredients business and operations to Bain Capital and Cinven, two private equity firms.

Lonza to Divest its Specialty Ingredients Business and Operations for $4.2 Billion

FDA considers regulatory flexibility to allow the agency and sponsors to adapt and pivot to changes in coronavirus. 

FDA Outlines Strategy to Address Virus Variants

Through the acquisition, Jazz will gain access to GW’s novel cannabinoid platform, including Epidiolex, a plant-derived cannabinoid medicine for the treatment of high-growth childhood-onset epilepsy.

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals for $7.2 Billion

The deal, which is set to close by the end of the first quarter of 2021, will provide Horizon with access to Viela’s rare disease medicine portfolio. 

Horizon Therapeutics to Acquire Viela Bio for $3 Billion

The vaccine will be developed using Gritstone’s proprietary prime-boost vaccine platform, which includes self-amplifying mRNA and adenoviral vectors, with antigens formulated by Gilead.

Gilead and Gritstone Initiate $785 Million HIV Vaccine Collaboration

Through the acquisition, Lilly will have access to Prevail’s portfolio of clinical-stage and preclinical neuroscience assets.

Eli Lilly Completes $1.5 Billion Acquisition of Prevail Therapeutics

The companies will develop up to three CD3-engaging T-cell redirecting bispecific antibody therapies using Merus' proprietary Biclonics platform.

Loxo Oncology at Lilly and Merus Enter into Bispecific Antibody Partnership for up to $1.6 Billion

Henogen will be integrated into Thermo Fisher’s Pharma Services business within its Laboratory Products and Services segment.

Thermo Fisher Completes $875-Million Acquisition of Novasep’s Viral Vector Manufacturing Business

This new agreement covers 1.25 million additional doses of the antibody cocktail containing casirivimab and imdevimab for the treatment of COVID-19.

US Government to Purchase Additional Doses of Regeneron’s COVID-19 Antibody Cocktail

The acquisition will give Sanofi full global rights to KY1005, Kymab’s fully human monoclonal antibody that binds to OX40-Ligand, giving it the potential to treat a variety of immune-mediated diseases and inflammatory disorders. 

Sanofi to Acquire Kymab for $1.4 Billion

The new facility, which will be operated by Fujifilm Diosynth Biotechnologies, will provide large-scale cell-culture manufacturing of bulk drug substance with 8 x 20,000-L bioreactors.

Fujifilm to Invest Over $2 Billion into US Biopharmaceutical Manufacturing Facility  

Angelini will obtain an exclusive license to commercialize Arvelle’s investigational anti-seizure medication, cenobamate, in the European Union and other countries in the European Economic Area.

Angelini Pharma to Acquire Arvelle Therapeutics for $960 Million

Honeywell will use Sparta’s expertise to introduce new QMS solutions for life sciences to its customer base.

Top News